Protalix Biotherapeutics Inc V.PLX.H

Primary Symbol: PLX

Healthcare Biotechnology

Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of severe gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its product, Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase)- a chemically modified enzyme under development for the potential treatment of severe gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate.

NYSEAM:PLX - Post by User

Protalix Biotherapeutics Inc > Very illiquid

<< Previous

Bullboard Posts

Next >>

Comment by Maxmoeon Jun 19, 2019 10:21am

74 Views

Post# 29839733

RE:RE:RE:Very illiquid

‘Roughly the same production’? Not even close. Pul has plenty of puffery but next to nothing regarding hard data. I don’t see boe/d in Q1 sedar for pul but it’s there for plx. Before the wizard comes on. It’s 720 boe/d in Q1. Revenue comparison in $ is possible. Plx is 3X the size of pul, not ‘roughly the same’. You likely know the answer to your own questions. If not go to sedar and read annual report,aif,etc. sedi is the best source for insider and large shareholder info.

<< Previous

Bullboard Posts

Next >>

Invest wiser with BMO's InvestorLine Platform features